ATOM study - Phase 3 RCT testing abaloparatide (Tymlos) in 228 men with osteoporosis. At 12 mos Tymlos shows signif increase in lumbar BMD of 1.2%. Also increased were hip and femoral neck BMD at 12 months. https://t.co/WC3ygkyMZH